The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer.
 
Benjamin Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Wallace Akerley
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Other Relationship - Lilly
 
Vinod Ganju
Honoraria - AstraZeneca; Roche/Genentech
 
Jun Zhang
Consulting or Advisory Role - AstraZeneca; Fosun Pharma; Novocure; Regeneron; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; MJH Life Sciences; Regeneron; Sanofi
Research Funding - Abbvie (Inst); AstraZeneca; BeiGene (Inst); Bridgebio (Inst); Champions Oncology; Genentech/Roche; Hengrui Therapeutics (Inst); Innocare (Inst); Janssen (Inst); KAHR Medical (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics; Mirati Therapeutics (Inst); Nilogen Oncosystems; Novartis (Inst); Takeda
 
Alex Adjei
Consulting or Advisory Role - EMD Serono; Iambic; Mirati Therapeutics; Swiss Rockets
Research Funding - BioNtech (Inst); BridgeBio Pharma (Inst); Kronos Bio (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Merck KGaA; Swiss Rockets; Zai Lab
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Lei Deng
Honoraria - MJH Life Sciences; Precisca
Consulting or Advisory Role - Bristol-Myers Squibb; Regeneron
Research Funding - Bridgebio
Travel, Accommodations, Expenses - Merck; MJH Life Sciences
 
Edward Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; Arcus Biosciences; ArriVent Biopharma; AstraZeneca; Atreca; Black Diamond Therapeutics; BridgeBio Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Hexagon; Hookipa Biotech; I-Mab; ITeos Therapeutics; LianBio; Lilly; Merck; Merus; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Sanofi; Seagan; Strata Oncology; Sumitomo Pharma Oncology; Summit Therapeutics; Synthekine
Research Funding - ABL Bio (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); BridgeBio Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Synthekine (Inst); TILT Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - Daiichi Sankyo/Astra Zeneca
 
So Yeon Kim
Consulting or Advisory Role - Amgen; Genentech; Revolution Medicines
Research Funding - AstraZeneca (Inst); Bioinvent (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Bristol Myers Squibb Foundation (Inst); DynamiCure Biotechnology (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
 
Richard Frank
No Relationships to Disclose
 
Lyudmila Bazhenova
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Bayer; BioAtla; BMS GmbH & Co. KG; Boehringer Ingelheim; daichi; Genentech/Roche; Gilead Sciences; Janssen Oncology; Merck; Natera; neuvogen; Novocure; Pfizer; Regeneron; Sanofi; Summit pharmaceuticals; Teligene
 
Rasha Cosman
No Relationships to Disclose
 
Rachel Roberts-Thomson
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharpe Dohme; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca; Bristol Myer Squibb; Merck Sharpe Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Christos Karapetis
Honoraria - Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; BMS; Boehringer Ingelheim; Gilead Sciences; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Takeda
 
Yong Ben
Employment - BridgeBio Oncology Therapeutics
Leadership - BridgeBio Oncology Therapeutics; Corbus Pharmaceuticals
Stock and Other Ownership Interests - BeiGene; BridgeBio Oncology Therapeutics; Corbus Pharmaceuticals
Consulting or Advisory Role - Allist Pharmaceuticals; Eight Roads Venture China
Travel, Accommodations, Expenses - AlphaGen; BridgeBio Oncology Therapeutics
 
Foster Gonsalves
Employment - Bridgebio; Rgenix
Leadership - Rgenix
Stock and Other Ownership Interests - Rgenix
Patents, Royalties, Other Intellectual Property - Rgenix
Travel, Accommodations, Expenses - Rgenix